AzTrials
AzTrials

TuberculosisNCT02581579

Study to Evaluate the Tolerability and Immunogenicity of Nyaditum Resae ® Probiotic Administered to Pediatric Population in Contact With Tuberculosis With or Without Latent Tuberculosis Infection

A study testing Nyaditum resae ® 10e5 of heat-killed Mycobacterium manresensis in people with Tuberculosis, run by Manresana de Micobacteriologia, SL at 3 sites in Spain.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This is a doble-blind, masked, compared with placebo clinical trial in pediatric population in contact with tuberculosis with or without tuberculosis infection. This trial aims to study the effect of the probiotic Nyaditum resae® at the level of specific Treg memory cells eight weeks after the first administration… Read more about this study

Who is it for?
Ages 2 to 17 yearsHealthy volunteers can take part
Conditions the study is for
Tuberculosis
What is being tested?
Nyaditum resae ® 10e5 of heat-killed Mycobacterium manresensis
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
24 participants
Where
3 sitesSpain
Study dates
9 Dec 2015to 6 Mar 2019
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 2 to 17 years
  • All sexes
  • Healthy volunteers accepted
  • Child

Who may be able to join

  • Child from a study of contact with tuberculosis. Obtaining informed consent from parents / mothers or guardians and, over 12 years, obtaining the consent of the child.
  • Child between 2 and 17 years (inclusive) on the day of obtaining informed consent.
  • Willingness to fulfill the requirements of the protocol.

Who cannot join

  • Active tuberculosis. Enrollment in another clinical trial or study with sanitary product involving invasive techniques.
  • Chronic administration of: methotrexate, azathioprine, cyclophosphamide, oral corticosteroids (≥500mg cumulative prednisone dose, or equivalent; inhaled or topical steroids are allowed) and other immunosuppressive therapies / immunomodulatory .
  • Administration of blood products or blood derivatives during the 6 months prior to randomization.
  • Vaccination in the month prior to randomization. Anticipation of receiving vaccines duration of the study.
  • Detection by the researcher lack of knowledge or willingness to participate and fulfill all the requirements of the protocol.
  • Any other finding that the investigator's opinion, could jeopardize the performance of the protocol or significantly influence the results or interpretation of the effects of probiotic.
  • Known immunodeficiencies. Pregnancy or breastfeeding. Hypersensitivity to mannitol

Trial locations and contacts

3 sites in 1 country.

Spain3 sites
  • Germans Trias I Pujol Hospital

    Badalona, Barcelona, 08916

  • Valle Hebron Hospital

    Barcelona, 08035

  • Hospital Sant Joan de Déu

    Esplugues de Llobregat, Barcelona, 08950

Other trials in Spain

About this study

Official title: Pilot Phase I Clinical Trial, Double-blind, Randomized, Placebo Controlled and Masked to Evaluate the Tolerability and Immunogenicity of Nyaditum Resae ® Probiotic Administered to Pediatric Population in Contact With Tuberculosis With or Without Latent Tuberculosis Infection

This is a doble-blind, masked, compared with placebo clinical trial in pediatric population in contact with tuberculosis with or without tuberculosis infection. This trial aims to study the effect of the probiotic Nyaditum resae® at the level of specific Treg memory cells eight weeks after the first administration, and the global tolerability of the treatment.

Nyaditum resae® is a preparation in the form of capsules containing heat-killed environmental mycobacteria Mycobacterium manresensis. The overall objective of the study is the effect of Nyaditum resae® on immunity, which could reduce the risk of developing active tuberculosis.

Read the detailed description

The incidence of tuberculosis is still a problem of the first magnitude. Every year 1.5 million people die; there are 10 million cases of illness and 100 million new infected. The growing problem of multi-resistance is to be added, remaining so prevalent: 700,000 patients, a figure that increases annually with 100,000 people. Prevention of tuberculosis is currently very difficult because it is a disease caused by a bacillus (Mycobacterium tuberculosis) that is transmitted by air: No risk factor for becoming infected has been identified and there is still no prophylactic vaccine that prevents from infection. One of the most characteristic aspects of tuberculosis is that the majority (90-95 %) of people without immunity alterations do not develop the disease after being infected. As for people who do develop the disease, it is still not known why they develop it.

A group of researchers from the Institut Germans Trias i Pujol recently discovered a mechanism that explains this trend. In short, what happens is that certain people create a too strong inflammatory response against tuberculosis bacillus, which ends up creating massive destruction of the tissue that is around the bacillus and brings the characteristic lesion of tuberculosis: tuberculous cavity.

This group of researchers was devising ways to "reeducate" the immune system against the bacillus not make it aggressive. And they did it using two instruments. The first one, an environmental mycobacteria, namely a bacillus of the family of mycobacteria tuberculosis, that usually lives in the water we drink, so that at a greater or lesser extent we already have it in our intestinal flora. The second, inducing a tolerant response, like we do when we eat food. To induce a tolerant response, low and repeated doses of the product make the immune system of the digestive duct "used to" their presence. Thus, when it becomes to find the product, the immune system reacts in a very light and balanced manner, avoiding excessive inflammatory responses. The clearest example is the fact that our immune system "is used" to feed proteins and generates no rejection answers found in the intestinal mucosa.

Hence comes the probiotic Nyaditum resae®, a preparation in the form of capsules, containing a heat-killed Mycobacterium manresensis and thus can generate a cross-immunity with the tuberculosis bacillus. By giving low and repeated dose to generate a tolerant response, which happens when there is an infection by Mycobacterium tuberculosis, so that a balanced immune response is triggered able to reduce the risk of developing active tuberculosis.

Tolerability of Nyaditum resae® has been studied in adults. Next step is to asses its behavior in pediatric population, since is a particularly vulnerable population in countries where there is a high incidence of this disease.

Conditions
Tuberculosis
Being tested
Nyaditum resae ® 10e5 of heat-killed Mycobacterium manresensis, Placebo
Keywords
Tuberculosis, Tregs, Tolerance, Probiotic, Mycobacteria
Medical subject headings
Tuberculosis, Mycobacterium Infections

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Nyaditum resae ® 10e5 of heat-killed Mycobacterium manresensisDietary supplement

    Nyaditum resae ® 10e5 of heat-killed Mycobacterium manresensis, 1 capsule per day during 14

  • PlaceboOther

    Placebo, 1 capsule per day during 14

Study groups in NCT02581579
Study groupRoleWhat they receive
Nyaditum resae ® 10e5 of heat-killed Mycobacterium manresensisActive comparatorNyaditum resae ® 10e5 of heat-killed Mycobacterium manresensis
Receives: Dietary Supplement: Nyaditum resae ® 10e5 of heat-killed Mycobacterium manresensis
PlaceboPlacebo comparatorMANITOL CAPSULES
Receives: Other: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change from Baseline in Specific Treg memory cells at week 1

    Measured: From Baseline to Week 8

  2. Proportion of patients presenting adverse events related to study treatment.

    Measured: From Baseline to Week 8

Secondary outcomes (2)
  1. Proportion of participants presenting gastrointestinal adverse events related to study treatment.

    Measured: Baseline to week 8

  2. Proportion of participants presenting systemic adverse events related to study treatment.

    Measured: Baseline to week 8

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted21 Oct 2015 (estimated)
  2. Study start9 Dec 2015
  3. Primary completion6 Mar 2019
  4. Study completion6 Mar 2019

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Masking
Triple blind
Who is masked
Participant, Care provider, Investigator
Enrolment
24 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02581579
Sponsor's protocol ID
NYADAPETRICS
Status last verified
Dec 2019
First submitted
19 Oct 2015
Last updated
4 Dec 2019
Results posted
No
Data monitoring committee
No

Publications

  • Tukvadze N, Cardona P, Vashakidze S, Shubladze N, Avaliani Z, Vilaplana C, Cardona PJ. Development of the food supplement Nyaditum resae as a new tool to reduce the risk of tuberculosis development. Int J Mycobacteriol. 2016 Dec;5 Suppl 1(Suppl 1):S101-S102. doi: 10.1016/j.ijmyco.2016.09.073. Epub 2016 Nov 14.

    PubMed 28043488

Questions about this trial

What is this clinical trial studying?

A study testing Nyaditum resae ® 10e5 of heat-killed Mycobacterium manresensis in people with Tuberculosis, run by Manresana de Micobacteriologia, SL at 3 sites in Spain.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 4 Dec 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 3 sites in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change from Baseline in Specific Treg memory cells at week 1 (time frame: From Baseline to Week 8). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02581579, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Dec 2019.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in